Independent minds. Global perspective. A publication for the builders
Biotechnology / Munich, Germany

Patrick Grossmann.

Co-founder
Invitris

Patrick Grossmann is a founder of Invitris, a biotechnology company developing systems for producing protein based drugs. His training includes bioinformatics, a doctorate and an MBA, with academic experience at Harvard Medical School and ETH Zurich. The company describes a cell free production platform and an initial focus on bacteriophages.

Public-source researchLast checked 1 source ↘
THE STORY, IN CONTEXT

Patrick Grossmann and the story of Invitris.

Invitris' launch presents Phactory as a platform for synthesising proteins from DNA using machinery derived from cells. Its founders identify bacteriophages as an initial application and explicitly seek partners in biopharmaceutical development, animal health and agriculture. The story concerns a production platform and the collaborations needed to develop products around it. Public launch statements about efficiency or possible treatments do not establish clinical outcomes or regulatory status.

FROM THE PUBLIC RECORD

Public advice & further reading.

No personal advice is attributed in this profile: a verifiable public advice source has not yet been established. The company and activity facts above remain separately sourced.

Suggest a first-person interview or essay ↗
EVIDENCE IN PLAIN SIGHT

Sources & attribution.

  1. 01
    Invitris — Y Combinator company and active founder profile

    Public active-founder biography, current company status and description, and founding-team launch accounts. Company or team statements are attributed accounts, not independently audited performance results.

    www.ycombinator.com
About this profile

Independently researched from the public sources above. Featured people and companies are not affiliated with BusinessBlogz. Source dates and attribution provide context for the information shown; business claims remain attributed to their original source. Role and company details can change after review. The initials graphic is editorial artwork, not a photograph.

Request a correction or update ↗
KEEP EXPLORING

More builders in Biotechnology.

Explore the sector ↗